(Q33845886)

29 July 2017

1 reference

title

Physicochemical drug properties associated with in vivo toxicological outcomes: a review (English)

1 reference

29 July 2017

Lyn Jones

3

0 references

author name string

David A Price

1

1 reference

29 July 2017

Julian Blagg

2

1 reference

29 July 2017

Nigel Greene

4

1 reference

29 July 2017

Travis Wager

5

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 August 2009

1 reference

Expert Opinion on Drug Metabolism & Toxicology

29 July 2017

1 reference

29 July 2017

5

1 reference

29 July 2017

921-931

1 reference

29 July 2017

8

1 reference

The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates

29 July 2017

1 reference

https://api.crossref.org/works/10.1517%2F17425250903042318

Can the pharmaceutical industry reduce attrition rates?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903042318

The future of drug safety testing: expanding the view and narrowing the focus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903042318

Assessing the emetic potential of PDE4 inhibitors in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903042318

PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903042318

Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of respiratory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903042318

Fluorescently labeled analogues of dofetilide as high-affinity fluorescence polarization ligands for the human ether-a-go-go-related gene (hERG) channel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903042318

Toxicophores, reactive metabolites and drug safety: when is it a cause for concern?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903042318

Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903042318

The pathologist and toxicologist in pharmaceutical product discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903042318

The metabolism and toxicity of quinones, quinonimines, quinone methides, and quinone-thioethers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903042318

The Role of Hydrophobicity in Toxicity Prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903042318

Overcoming HERG affinity in the discovery of the CCR5 antagonist maraviroc

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903042318

The influence of drug-like concepts on decision-making in medicinal chemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903042318

Drug-like properties and the causes of poor solubility and poor permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903042318

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903042318

Property-based design: optimization of drug absorption and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903042318

Trends in development and approval times for new therapeutics in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903042318

Characteristic physical properties and structural fragments of marketed oral drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903042318

A comparison of physiochemical property profiles of development and marketed oral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903042318

The evolution of synthetic oral drug properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903042318

Physiochemical drug properties associated with in vivo toxicological outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903042318

Modeling promiscuity based on in vitro safety pharmacology profiling data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903042318

Can we rationally design promiscuous drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903042318

Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903042318

Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903042318

Identifying Important Risk Factors for Survival in Kidney Graft Failure Patients Using Random Survival Forests

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903042318

Effects of membrane partitioning and other physical chemical properties on the apparent potency of "membrane active" compounds evaluated using red blood cell lysis assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903042318

Biomarkers to monitor drug-induced phospholipidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903042318

Drug-induced phospholipidosis: issues and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903042318

Experimental myopathy induced by amphiphilic cationic compounds including several psychotropic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903042318

Silymarin and vitamin E reduce amiodarone-induced lysosomal phospholipidosis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903042318

An aminomethylpyrimidine DPP-IV inhibitor with improved properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903042318

Mechanism of mitochondrial uncouplers, inhibitors, and toxins: focus on electron transfer, free radicals, and structure-activity relationships

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903042318

Role of quinones in toxicology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903042318

Mitochondrial redox cycling of mitoquinone leads to superoxide production and cellular apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903042318

Production of hydrogen peroxide and redox cycling can explain how sanguinarine and chelerythrine induce rapid apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903042318

Acute liver injury related to the use of niperotidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903042318

Cutaneous photosensitivity diseases induced by exogenous agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903042318

Comparative QSAR evidence for a free-radical mechanism of phenol-induced toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903042318

Comparative QSAR: on the toxicology of the phenolic OH moiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903042318

Structure-activity relationship studies of chemical mutagens and carcinogens: mechanistic investigations and prediction approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903042318

Extended quantitative structure-activity relationships for 80 aromatic and heterocyclic amines: structural, electronic, and hydropathic factors affecting mutagenic potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903042318

Application of quantitative structure-toxicity relationships for acute NSAID cytotoxicity in rat hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903042318

Testing paradigm for prediction of development-limiting barriers and human drug toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903042318

Concordance of the toxicity of pharmaceuticals in humans and in animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903042318

First dose of potential new medicines to humans: how animals help

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903042318

Prospects for reducing and refining the use of dogs in the regulatory toxicity testing of pharmaceuticals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903042318

Development of a high throughput in vitro toxicity screen predictive of high acute in vivo toxic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903042318

Research perspectives for pre-screening alternatives to animal experimentation: on the relevance of cytotoxicity measurements, barrier passage determinations and high throughput screening in vitro to select potentially hazardous compounds in large s

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903042318

Data completeness—the Achilles heel of drug-target networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903042318

10.1517/17425250903042318

21 January 2018

Identifiers

DOI

1 reference

29 July 2017

1 reference